Aryl pyridazinone derivatives and their use as H3 receptor ligands
US8586588B2 · kind B2 · utility
1Cited by
25References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 15, 2010 |
| Grant date | Nov 19, 2013 |
| Priority date | — |
| Expiry date | Apr 24, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.